HOUSTON--(BUSINESS WIRE)-- DXP Enterprises, Inc. (NASDAQ: DXPE) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. The following are results for the three and twelve months ended December 31, 2024, compared to the three and twelve months ended December 31, 2023. A reconciliation of the non-GAAP financial measures can be found in the back of this press release. Fourth Quarter 2024 financial highlights: Sales were $470.9 million for the fourth quarter of 2024, compared to $407.0 million for the fourth quarter of 2023. Diluted earnings per share...
HOUSTON--(BUSINESS WIRE)-- DXP Enterprises, Inc. (the “Company”) (NASDAQ: DXPE), a leading business to business products and service distributor that adds value and total cost savings solutions to MRO and OEM customers in virtually every industry, plans to issue a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024, on Thursday, March 6th. The earnings announcement will be released after the market closes. DXP will host a conference call, to be web cast live, on the Company’s website () at 10:30 AM Central Time on Friday, March 7th. Th...
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated. As a result, the board of directors will reassess the Company’s strategic alternatives, including out-licensing, merger and acquisition opportunities (including reverse mergers), the sale of assets and technologies, and winding down operations, among o...
Seneca Foods Reports Sales and Earnings for the Quarter and Nine Months Ended December 28, 2024 FAIRPORT, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the third quarter and nine months ended December 28, 2024. Executive Summary (vs. year-ago, year-to-date results): Net sales for the nine months ended December 28, 2024 totaled $1,233.0 million compared to $1,150.6 million for the nine months ended December 30, 2023. The year-over-year increase of $82.4 million was due mainly to higher sales v...
HOUSTON--(BUSINESS WIRE)-- DXP Enterprises, Inc. (NASDAQ: DXPE) today announced that it has completed the acquisition of Arroyo Process Equipment (“Arroyo”). Founded in 1968, Arroyo is headquartered in Bartow, Florida and operates out of three locations servicing northern, central, and southern Florida, and surrounding markets. Arroyo is a leading distributor of pumps, process equipment, and related service and repairs focused on serving the asphalt, mining, industrial water, chemical and other industrial markets. DXP funded the acquisition with cash from the balance sheet. “We are pleased...
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 Companies also provide insights into proposed strategic merger SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data f...
Vincerx Pharma, Inc. Announces Reverse Stock Split Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which will be effective as of January 27, 2025 at 4:01 p.m., Eastern Time. Vincerx’s common stock will cont...
In this product we rank the most positive and negative domestic stocks, filter the symbols bymarket-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 Also Exploring Strategic Alternatives to Complement Fundraising Efforts PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the Company’s novel CD123-targeted antibody-drug conjugate (ADC) developed with the Company’s ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.